Assessment of Safety and Preliminary Efficacy With BAT6021 in Solid Tumor Patients
- Registration Number
- NCT05073484
- Lead Sponsor
- Bio-Thera Solutions
- Brief Summary
This first-in-human open-label, multi center, dose-escalation and expansion study is designed to evaluate the safety, tolerability, and PK of BAT6021 alone or in combination with BAT1308 (an anti-PD-1 antibody) in participants with locally advanced, recurrent, or metastatic incurable tumors for whom standard therapy does not exist, has proven to be ineffective or intolerable, or is considered inappropriate, or for whom a clinical trial of an investigational agent is a recognized standard of care.
- Detailed Description
Anti-PD-1 and anti-PD-L1 antibodies targeting the immuno-inhibitory PD-1 pathway (thus activating T cells) have achieved clinical success in many types of cancers. However, studies have shown that anti-TIGIT antibodies not only trigger T cells and Natural Killer(NK) cells, but they can also activate T cells to a greater extent than anti-PD-1 antibodies. Therefore, further clinical investigation of anti-TIGIT antibodies such as BAT6021 is warranted.
PD-1 and TIGIT are commonly co-expressed in T cells of the same tumor; thus, combining anti-TIGIT antibodies with PD-1/PD-L1 inhibitors may be a more effective cancer treatment. Indeed, anti-TIGIT antibodies have demonstrated synergy with anti-PD-1/PD-L1 antibodies in preclinical models. In addition, sponsor have shown that single administration of BAT1308 or BAT6021 could not effectively inhibit CT26 tumor growth in PD-1/TIGIT- humanized syngeneic mice; however, the combination treatment resulted in potent anti-tumor activity. Therefore, combined treatment with BAT6021 and an anti-PD-1/PD-L1 antibody like BAT1308 could improve therapeutic outcomes.
Recruitment & Eligibility
- Status
- TERMINATED
- Sex
- All
- Target Recruitment
- 13
- Able to give voluntary informed consent and understand the study and are willing to follow and complete all the test procedures.
- Aged ≥ 18 years.
- Life expectancy ≥ 3 months.
- ECOG performance status ≤ 1.
- Histologically/cytologically confirmed, locally advanced unresectable or metastatic solid tumors that are refractory to standard therapy, or for whom no standard therapy exists.
- Has measurable disease per RECIST v1.1. that was not in a prior radiation or other locally treated area, unless imaging-based progression has been clearly documented following radiation or other local therapy.
- Females who are pregnant or nursing.
- Receiving concurrent anticancer therapy or investigational therapy (including chemotherapy, radiation therapy, surgery, immunotherapy, hormonal therapy, targeted therapy, biologic therapy).
- Has remaining AEs > Grade 1 from prior antitumor treatment as per CTCAE v5.0, with the exception of alopecia.
- Participants with primacy central nervous system (CNS) malignancy, symptomatic CNS metastases, meningeal metastases or leptomeningeal disease are not allowed. Note: Participants with asymptomatic CNS metastases are eligible if clinically controlled, which is defined as 1) ≥ 4 weeks of stable neurologic function following CNS-directed therapy prior to Screening, 2) no evidence of CNS disease progression as determined by radiographic imaging ≥ 4 weeks prior to Screening, 3) ≥ 2 weeks from discontinuation of anti-seizure and steroid therapies (receiving prednisone ≤ 10mg or equivalent steroid therapies is allowed) prior to Screening.
- Had major surgery within 28-days of the Screening Visit. Note: Participants who have undergone a non-major surgical procedure ≥ 28 days prior to Screening must have recovered adequately from the toxicity and/or complications from the intervention before administration of the first dose of study drugs.
- History of tissue or organ transplantation.
- History of severe infection deemed clinically significant by the PI or designee within 4 weeks or signs and symptoms of any active infection within 2 weeks prior to the first dose of study drugs.
- History of human immunodeficiency virus (HIV) infection or history of autoimmune diseases.
- Active hepatitis B or C. Note: Hepatitis B virus (HBV) carriers without active disease (HBV DNA titer < 1000 copies/mL or 200 IU/mL) or cured Hepatitis C (negative HCV RNA test) may be enrolled.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SEQUENTIAL
- Arm && Interventions
Group Intervention Description 10 mg of BAT6021 BAT6021 BAT6021 100mg/vial，10mg Ⅳ infusions 600mg BAT6021+300mg BAT1308 BAT1308 BAT6021 100mg/vial，BAT1308 100mg/vial ; BAT6021 600mg+BAT1308 300mg Ⅳ infusions 300mg BAT6021+300mg BAT1308 BAT1308 BAT6021 100mg/vial，BAT1308 100mg/vial ; BAT6021 300mg+BAT1308 300mg Ⅳ infusions 300 mg of BAT6021 BAT6021 BAT6021 100mg/vial，300mg Ⅳ infusions 30 mg of BAT6021 BAT6021 BAT6021 100mg/vial，30mg Ⅳ infusions 100 mg of BAT6021 BAT6021 BAT6021 100mg/vial，100mg Ⅳ infusions 600 mg of BAT6021 BAT6021 BAT6021 100mg/vial，600mg Ⅳ infusions 100mg BAT6021+300mg BAT1308 BAT6021 BAT6021 100mg/vial，BAT1308 100mg/vial ; BAT6021 100mg+BAT1308 300mg Ⅳ infusions 300mg BAT6021+300mg BAT1308 BAT6021 BAT6021 100mg/vial，BAT1308 100mg/vial ; BAT6021 300mg+BAT1308 300mg Ⅳ infusions 600mg BAT6021+300mg BAT1308 BAT6021 BAT6021 100mg/vial，BAT1308 100mg/vial ; BAT6021 600mg+BAT1308 300mg Ⅳ infusions 900 mg of BAT6021 BAT6021 BAT6021 100mg/vial，900mg Ⅳ infusions 100mg BAT6021+300mg BAT1308 BAT1308 BAT6021 100mg/vial，BAT1308 100mg/vial ; BAT6021 100mg+BAT1308 300mg Ⅳ infusions
- Primary Outcome Measures
Name Time Method Serious adverse event（SAE） From the time of informed consent to 90 days after the last dose or until the initiation of a new cancer treatment. Any SAE that is judged by the PI or designee to be related to the study medication must be reported regardless of the amount of time since the last dose received. Follow-up information collected for any initial report of an SAE must also be reported to the Sponsor (or its designee) within 24 hours of receipt by the PI or designee.
Dose-limiting toxicity(DLT) A minimum of 21 days after first dose of BAT6021 DLT is defined as one of the following as investigator related to study drug:
Grade 5 toxicity; Hematologic Toxicity ; ≥ Grade 4 anemia; Grade 4 thrombocytopenia that lasts for ≥ 7 days or Grade 3 thrombocytopenia, if associated with clinically significant bleeding (≥ Grade 2 hemorrhage) or requires transfusion of platelets; Grade 4 neutropenia that lasts for ≥ 7 days, or Grade 3 neutropenia that lasts for ≥ 7 days or with documented infection; Grade 3 or Grade 4 febrile neutropenia of any duration.
- Secondary Outcome Measures
Name Time Method Pharmacokinetics (PK) every cycle until cycle 6 (one cycle equals 3 weeks) Cmax
Immunogenicity every cycle until cycle 6 (one cycle equals 3 weeks) Presence of ADAs / neutralizing antibodies (NAbs).
Trial Locations
- Locations (3)
Macquarie University Hospital
🇦🇺Sydney, New South Wales, Australia
Liverpool Hospital
🇦🇺Liverpool, New South Wales, Australia
Cabrini Hospital Malvern
🇦🇺Melbourne, Victoria, Australia